SCHEMBL1936151

SCHEMBL1936151

COC(=O)c1sccc1S(=O)(=O)Nc1cccc(OC)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.60
PPARD Q03181 1/20 0.60
PPARA Q07869 1/20 0.60
LMNA P02545 4/20 0.57
HPGD P15428 1/20 0.57
MAPT P10636 2/20 0.56
EDNRA P25101 4/20 0.55
EDNRB P24530 1/20 0.55
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
ALDH1A1 P00352 2/20 0.54
PKM P14618 1/20 0.54
TSHR P16473 1/20 0.51
HTT P42858 1/20 0.51
TCF4 P15884 1/20 0.51
CTNNB1 P35222 1/20 0.51
TP53 P04637 1/20 0.50
GAA P10253 1/20 0.50
HSD17B10 Q99714 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1936832 0.90 MEN1 (0.57) PPARGPPARDPPARALMNAHPGD
SCHEMBL12293579 0.88 PPARG (0.57) PPARGPPARDPPARALMNAMAPT
SCHEMBL12293613 0.88 TCF4 (0.60) PPARGPPARDPPARAMAPTEDNRA
SCHEMBL14702211 0.88 MAPT (0.58) PPARGPPARDPPARAHPGDMAPT
SCHEMBL12293572 0.86 CCR2 (0.57) PPARGPPARDPPARAHPGDMAPT
SCHEMBL12293580 0.86 PPARG (0.56) PPARGPPARDPPARALMNAMAPT
SCHEMBL12293574 0.86 KDM4E (0.59) PPARGPPARDPPARALMNAMAPT
SCHEMBL533130 0.85 PPARG (0.66) PPARGPPARDPPARALMNAMAPT
SCHEMBL14702206 0.85 PKM (0.61) PPARGPPARDPPARALMNAHPGD
SCHEMBL12293623 0.85 PPARG (0.58) PPARGPPARDPPARALMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110263691-A1 METHODS CONCERNING PPAR DELTA AND ANTAGONISTS THEREOF UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2011-10-27 US claimed
EP-2331697-A2 METHODS CONCERNING PPAR DELTA AND ANTAGONISTS THEREOF University Court of The University of Dundee (GB) 2011-06-15 EP claimed
WO-2010013071-A2 METHODS CONCERNING PPAR DELTA AND ANTAGONISTS THEREOF UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2010-02-04 WO claimed
US-9155289-B2 Methods concerning PPAR delta and antagonists thereof UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2015-10-13 US disclosed
US-9155289-B2 Methods concerning PPAR delta and antagonists thereof UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2015-10-13 US disclosed
EP-2331697-B1 METHODS CONCERNING PPAR DELTA AND ANTAGONISTS THEREOF UNIV DUNDEE (GB) 2015-03-25 EP disclosed
US-8895608-B2 Sulfonamide anti-viral compounds Kineta, Inc. (US) 2014-11-25 US disclosed
US-8895608-B2 Sulfonamide anti-viral compounds Kineta, Inc. (US) 2014-11-25 US disclosed
US-20130039945-A1 Anti-Viral Compounds Kineta, Inc. (US) 2013-02-14 US disclosed
US-20130039945-A1 Anti-Viral Compounds Kineta, Inc. (US) 2013-02-14 US disclosed
WO-2011133729-A2 ANTI-VIRAL COMPOUNDS Kineta, Inc. (US) 2011-10-27 WO disclosed
US-20110263691-A1 METHODS CONCERNING PPAR DELTA AND ANTAGONISTS THEREOF UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2011-10-27 US disclosed
US-20110263691-A1 METHODS CONCERNING PPAR DELTA AND ANTAGONISTS THEREOF UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2011-10-27 US disclosed
EP-2331697-A2 METHODS CONCERNING PPAR DELTA AND ANTAGONISTS THEREOF University Court of The University of Dundee (GB) 2011-06-15 EP disclosed
EP-2331697-A2 METHODS CONCERNING PPAR DELTA AND ANTAGONISTS THEREOF University Court of The University of Dundee (GB) 2011-06-15 EP disclosed
WO-2010013071-A3 METHODS CONCERNING PPAR DELTA AND ANTAGONISTS THEREOF UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2010-03-25 WO disclosed
WO-2010013071-A2 METHODS CONCERNING PPAR DELTA AND ANTAGONISTS THEREOF UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2010-02-04 WO disclosed
WO-2010013071-A2 METHODS CONCERNING PPAR DELTA AND ANTAGONISTS THEREOF UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2010-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263691-A1 METHODS CONCERNING PPAR DELTA AND ANTAGONISTS THEREOF PPARD, PPARG, PPARA PPARG 2/4885PPARD 1/4885PPARA 3/4885
US-20130039945-A1 Anti-Viral Compounds MAVS, EIF2AK2, IRF3 PPARG 2406/4885PPARD 2888/4885PPARA 3235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.